Clinical Trials Logo

Anaplastic Astrocytoma clinical trials

View clinical trials related to Anaplastic Astrocytoma.

Filter by:

NCT ID: NCT00610571 Completed - Glioblastoma Clinical Trials

Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas

Start date: April 2004
Phase: Phase 1
Study type: Interventional

Objectives: - To determine the maximum tolerated dose of oral topotecan when administered with Temodar to patients with malignant glioma - To characterize any toxicity associated with the combination oral topotecan and Temodar. - To observe patients for clinical antitumor response when treated with oral topotecan and Temodar.

NCT ID: NCT00606008 Completed - Glioblastoma Clinical Trials

A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma

Start date: March 2007
Phase: Phase 2
Study type: Interventional

We are asked patients to take part in this study because they had recurrent (returned) (1st or 2nd) anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM). The purposes of this study are: - To see if Sutent has any change on the patient and their cancer. - To see if Sutent will slow or stop the growth of their tumor. - To measure the safety of Sutent. Sutent is Food and Drug Administration (FDA) approved to treat patients with a gastrointestinal stromal tumor after the disease worsened while taking another medicine called imatinib mesylate or when imatinib mesylate cannot be taken. Sutent is also FDA approved to treat patients with advanced renal cell carcinoma. At this time, it is not known whether Sutent will improve symptoms, or help patients with this disease live longer.

NCT ID: NCT00589875 Completed - Clinical trials for Glioblastoma Multiforme

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

BrTK02
Start date: March 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the safety and potential efficacy of CAN-2409 (also known / previously described as AdV-tk, GMCI) for malignant gliomas. The approach used an adenoviral vector (disabled virus) engineered to express the Herpes thymidine kinase gene (aglatimagene besadenovec, CAN-2409), followed by an antiherpetic prodrug, valacyclovir. CAN-2409 was injected into the resection bed after standard tumor surgery and valacyclovir pills were taken for 14 days. Standard radiation and chemotherapy were administered which have been shown to work cooperatively with CAN-2409 + prodrug to kill tumor cells. The hypothesis is that this combination therapy can be safely delivered and will lead to improvement in the clinical outcome for patients with newly diagnosed malignant gliomas, including glioblastoma multiforme (WHO grade IV) and anaplastic astrocytomas (WHO grade III).

NCT ID: NCT00431561 Completed - Glioblastoma Clinical Trials

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Start date: April 2003
Phase: Phase 2
Study type: Interventional

In this multinational dose finding Phase IIb study the efficacy and safety of two doses of AP 12009 compared to standard chemotherapy (temozolomide or PCV) is investigated in adult patients with confirmed recurrent high-grade glioma.

NCT ID: NCT00430911 Completed - Clinical trials for Glioblastoma Multiforme

Radiotherapy for Malignant Astrocytomas in the Elderly

Start date: February 2001
Phase: Phase 3
Study type: Interventional

A randomized trial comparing radiotherapy with supportive care in patients aged 70 years or older with newly diagnosed, histologically confirmed anaplastic astrocytoma or glioblastoma, and a Karnofsky performance status > 70.

NCT ID: NCT00409214 Completed - Glioma Clinical Trials

Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma

Start date: November 2006
Phase: Phase 2
Study type: Interventional

The pupose of this study is to demonstrate the safety of the Litx™ therapy and confirm the zone of tumor destruction with escalated light doses following intraoperative treatment of primary or recurrent glioma.

NCT ID: NCT00390299 Completed - Clinical trials for Recurrent Glioblastoma

Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme

Start date: October 23, 2006
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of carcinoembryonic antigen-expressing measles virus (MV-CEA) in treating patients with glioblastoma multiforme that has come back. A virus, called MV-CEA, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.

NCT ID: NCT00301418 Completed - Clinical trials for Glioblastoma Multiforme

Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma

Start date: March 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This study will offer a safe treatment for patients with relapsing recurring glioblastoma (GBM) or anaplastic astrocytoma (AA). The trial will test the hypothesis that Erlotinib (Tarceva, OSI-774) can be safely used up to a dose of 150 mg two times a day for 12 months to ultimately enhance survival of patients with relapsed/refractory GBM/AA. Correlation of response to Tarceva with particular genetic alterations including epidermal growth factor receptor variant type III (EGFRvIII) amplification and phosphatase and tensin homolog (mutated in multiple advanced cancers 1) (PTEN) loss will be studied.

NCT ID: NCT00115440 Completed - Glioblastoma Clinical Trials

BNCT to Treat Glioma That Has Progressed Following Radiotherapy

Start date: March 2001
Phase: Phase 1/Phase 2
Study type: Interventional

Boron Neutron Capture Therapy (BNCT) is an experimental radiation therapy technique which is based on the principle of irradiating boron atoms with neutrons. When neutrons have relatively low energy, boron atoms that have been targeted to cancerous tissue using a suitable boron carrier (an amino acid derivative called BPA, boronophenylalanine) will capture the neutrons. As a result from the neutron capture the boron atoms will split into two, producing helium and lithium ions. The helium and lithium ions, in turn, have only a short pathlength in tissue (about 5 micrometers) and will deposit their cell damaging effect mainly within the tumor provided that the boron carrier (BPA) has accumulated in the tumor. In practice, the study participants will receive BPA as an approximately 2-hour intravenous infusion, following which the tumor is irradiated with low energy (epithermal) neutrons obtained from a nuclear reactor at the BNCT facility. BNCT requires careful radiation dose planning, but neutron irradiation will last approximately only for one hour. In this study BNCT is given once. The study hypothesis is that anaplastic astrocytomas and glioblastomas that have recurred following conventional radiotherapy might accumulate the boron carrier compound, and might respond to BNCT.

NCT ID: NCT00100802 Completed - Glioblastoma Clinical Trials

Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas

Start date: March 21, 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving radiation therapy together with temozolomide and lomustine works in treating young patients with newly diagnosed gliomas. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide and lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide and lomustine after surgery may kill any remaining tumor cells.